Search life-sciences literature (47,483,772 articles, preprints and more)

Exosome-Derived LncRNA MIR4435-2HG Suppresses Malignant Phenotypes and Brain Metastasis in Small Cell Lung Cancer

Mao X, Zhu Y, Jin Y, Yao W, Gan Jq, Bi Yn, Ge Yl, Sun Gg

Research Square, 19 Jan 2026

Cited by: 0 articles | PPR: PPR1145059

Reply to: "Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases," "Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials," and "Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases".

Aizer AA, Catalano PJ, Rahman R

J Clin Oncol, JCO2502528, 20 Jan 2026

Cited by: 0 articles | PMID: 41557968

The prognostic value of miR-323b-5p in non-small cell lung cancer and its mechanism of targeting IL1A in regulating the proliferation and cell cycle of non-small cell lung cancer cells.

Wu Y, Duan Z, Yan D, Yue J, Liu C

Discov Oncol, 23 Jan 2026

Cited by: 0 articles | PMID: 41575618

SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.

Marks JA, Sweeney K, Elliott A, Gupta B, VanderWalde A, Puri S, Shields MD, Nieva JJ, Soares HP, Ma PC, Halmos B, Liu SV

Lung Cancer, 213:108913, 10 Jan 2026

Cited by: 0 articles | PMID: 41534317

Correction to "Exosomal Long Interspersed Nuclear Element-1 Analytes Discriminate Histologic Subtypes, Sex, and Clinicopathological Characteristics of Patients With Non-Small Cell Lung Cancer".

MedComm (2020), 7(1):e70565, 04 Jan 2026

Cited by: 0 articles | PMID: 41497984 | PMCID: PMC12766155

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Targeting STAT3 by SH-4-54 suppresses the occurrence and inactivates oxidative phosphorylation in small-cell lung cancer via the SRC signaling.

Chen C, Hu H, Liu Z, Jiang Y, Shi M

Naunyn Schmiedebergs Arch Pharmacol, 21 Jan 2026

Cited by: 0 articles | PMID: 41563447

An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer.

Samaeekia R, Arter Z, Nagasaka M

Expert Rev Anticancer Ther, 18 Jan 2026

Cited by: 0 articles | PMID: 41548253

Real-world effectiveness and safety of atezolizumab-carboplatin-etoposide regimen in extensive-stage small-cell lung cancer.

Aznar de la Riera MB, Valencia Soto CM, García-Avello Fernández-Cueto A, Villacañas Palomares MV, Muñoz Unceta N, Fernández Martínez V, Barbadillo Villanueva S, Rioja Carrera M, Valero Dominguez M, Martínez Callejo V

Farm Hosp, S1130-6343(25)00182-5, 22 Jan 2026

Cited by: 0 articles | PMID: 41577571

Network pharmacology analysis and in vitro experimental validation of liriodenine against non-small cell lung cancer.

Yang J, Sun Y, Liang F, Shen Z, Zhou Y, Zhu J, Sun W, Xia Y

BMC Cancer, 26 Dec 2025

Cited by: 0 articles | PMID: 41454327

Erratum to "Response to "Regarding Dähler K et al." Evaluation of the prognostic value of the ESTRO/EORTC classification of reirradiation in patients with non-small cell lung cancer" [Radiother. Oncol. 213 (2025) 111214].

Willmann J, Andratschke N

Radiother Oncol, 216:111282, 09 Jan 2026

Cited by: 0 articles | PMID: 41518873

Erratum: Promotion of non-small cell lung cancer tumor growth by FHL2 via inducing angiogenesis and vascular permeability.

Editorial Office

J Thorac Dis, 17(12):11526-11530, 29 Dec 2025

Cited by: 0 articles | PMID: 41522111 | PMCID: PMC12780453

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

A New N2 Descriptor for Resectable Non-Small Cell Lung Cancer: The Classification Based on Skip Metastasis and the Number of N2 Station Involvement.

Huang X, Xu F, Cheng T, Yang H, Lu C, Ma T, Wang L, Ge D

World J Surg, 24 Jan 2026

Cited by: 0 articles | PMID: 41579337

Hsa_circ_0003176: a key player in the m6A modification-mediated regulation of autophagy and glycolysis in cisplatin-resistant non-small cell lung cancer.

Guo S, Yang Z, Qiao J, Rong L

Hum Cell, 39(2):38, 24 Jan 2026

Cited by: 0 articles | PMID: 41579303

From Simple Scores to Intelligent Systems: Encouraging the Development, Validation and Adoption of Robust Prognostic Tools in Small Cell Lung Cancer.

Cantale O, Oresti S, Randulfe I, Monaca F, Califano R

Technol Cancer Res Treat, 25:15330338261416810, 23 Jan 2026

Cited by: 0 articles | PMID: 41575930

Prognostic Impact of Preoperative Osteopenia for Patients with Resected Non-Small Cell Lung Cancer.

Nakanishi Y, Kinoshita F, Matsubara T, Akamine T, Kohno M, Ozono K, Ishigami K, Takenaka T, Nakamura M

Eur J Cardiothorac Surg, 68(1):ezaf481, 01 Jan 2026

Cited by: 0 articles | PMID: 41527282

The evolving role of radiotherapy in advanced non-small cell lung cancer: beyond symptom control.

Vianello M, Purshouse K, Fraser I, Phillips I

Ann Palliat Med, apm-25-103, 19 Jan 2026

Cited by: 0 articles | PMID: 41560507

Anti-angiogenesis effect of Baiying Juhua Decoction on the non-small cell lung cancer: integrating pharmacology, multi-machine learning and experimental investigation.

Meng X, Cao Y, Shen Q, Zhu H, Zhang J, Dong M

Bioresour Bioprocess, 13(1):5, 24 Jan 2026

Cited by: 0 articles | PMID: 41579221

In silico evaluation of (benzo)chromeno[3,4-c]pyridine derivative as dual EGFR/HER2 inhibitors for non-small cell lung cancer.

Luke U, Emeng IE, Gber NI, Iyam SO

Sci Rep, 23 Jan 2026

Cited by: 0 articles | PMID: 41577731

RETRACTION: Alternatively Expressed Transcripts Analysis of Non-Small Cell Lung Cancer Cells under Different Hypoxic Microenvironment.

Oncology JO

J Oncol, 2025:9836403, 19 Dec 2025

Cited by: 0 articles | PMID: 41497215 | PMCID: PMC12767088

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Comment on "leveraging readily available clinical data with machine learning to predict first-line immunotherapy outcomes in non-small cell lung Cancer".

Kumar S, Pinisetty R, Narayana VL

Int Immunopharmacol, 172:116160, 19 Jan 2026

Cited by: 0 articles | PMID: 41558299

Erratum: Neuroepithelial cell transforming 1 as a key regulator in non-small cell lung cancer: unveiling causal links and therapeutic potentials.

Editorial Office

Transl Cancer Res, 14(12):9099, 29 Dec 2025

Cited by: 0 articles | PMID: 41510125 | PMCID: PMC12776194

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Evaluation of Inflammatory Parameters and Ferritin as Prognostic Factors in Non-small Cell Lung Cancer Patients Receiving Nivolumab Immunotherapy.

Beypınar İ, Balçık OY, Urvay S, Ürün M, Erçek B, Demir H, Yıldız C, Araz M, Oruç A, İlhan Y, Özilice U, Kurtulus A

Biomarkers, 1-17, 24 Jan 2026

Cited by: 0 articles | PMID: 41579336

Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)

.

Ma H, Li L, Jiao C, Cheng Y, He J, Jiang C, Tong Q, Yi D, Zhang Y

Oncol Rep, 55(3):44, 16 Jan 2026

Cited by: 0 articles | PMID: 41543165

Antitumor effects of Santalol on non-small cell lung cancer via disruption of NF-κB-mediated lipid metabolism.

Meng J, Wu Y, Bu X, Li L, Chen J

J Transl Med, 20 Jan 2026

Cited by: 0 articles | PMID: 41559684

Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

[National Institute for Health and Care Excellence (NICE)][London], 07 Jan 2026

Cited by: 0 articles | NBK: NBK620046